Research & Literature

[Myelodysplastic syndromes and autoimmunity].

Stalder G, Alberio L, Ribi C

Revue medicale suisse 2015; (11(469)):820-2, 824-5.

The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Petrou E, Mavrogeni S, Karali V, et al.

Revista brasileira de hematologia e hemoterapia 2015; (37(4)):252-8.

Karyotype evolution and acquisition of FLT3 or RAS pathway alterations drive progression of myelodysplastic syndrome to acute myeloid leukemia.

Meggendorfer M, de Albuquerque A, Nadarajah N, et al.

Haematologica 2015; (100(12)):e487-90 doi:10.3324/haematol.2015.127985.

Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing.

Cazzola M, Malcovati L

Hematology. American Society of Hematology. Education Program 2015; (2015()):19-25 doi:10.1182/asheducation-2015.1.19.

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).

Schuler E, Giagounidis A, Haase D, et al.

Leukemia 2016; (30(7)):1580-2 doi:10.1038/leu.2015.340.

Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.

Escudero-Vilaplana V, Garcia-Gonzalez X, Osorio-Prendes S, et al.

Journal of clinical pharmacy and therapeutics 2016; (41(1)):59-63 doi:10.1111/jcpt.12348.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Kosmider O, Passet M, Santini V, et al.

Haematologica 2016; (101(7)):e280-3 doi:10.3324/haematol.2016.142695.

Effects of a home-based exercise program on physical capacity and fatigue in patients with low to intermediate risk myelodysplastic syndrome-a pilot study.

Schuler MK, Hentschel L, Göbel J, et al.

Leukemia research 2016; (47()):128-35.

CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload.

Bruch HR, Dencausse Y, Heßling J, et al.

Oncology research and treatment 2016; (39(7-8)):424-31 doi:10.1159/000447035.

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.

Komrokji RS

Clinical lymphoma, myeloma & leukemia 2016; (16 Suppl()):S39-43.

Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.

Jabbour E, Faderl S, Sasaki K, et al.

Cancer 2017; (123(4)):629-637 doi:10.1002/cncr.30383.

Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).

DeZern AE, Zeidan AM, Barnard J, et al.

Leukemia & lymphoma 2017; (58(6)):1325-1331 doi:10.1080/10428194.2016.1246726.

Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.

Lian XY, Zhang ZH, Deng ZQ, et al.

PloS one 2016; (11(11)):e0165948 doi:10.1371/journal.pone.0165948.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.

de Witte T, Bowen D, Robin M, et al.

Blood 2017; (129(13)):1753-1762 doi:10.1182/blood-2016-06-724500.

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

Radsak M, Platzbecker U, Schmidt CS, et al.

European journal of haematology 2017; (99(2)):112-118 doi:10.1111/ejh.12883.

Hematogones Detected by Flow Cytometry in a Child with Vitamin B12 Deficiency.

Sutton L, Mba N

Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 2017; (20(2)):172-175 doi:10.1177/1093526616686241.

[Mutational analysis of RNA splicing machinery genes SF3B1, U2AF1 and SRSF2 in 118 patients with myelodysplastic syndromes and related diseases].

Wang JY, Ma J, Lin YN, et al.

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017; (38(3)):192-197 doi:10.3760/cma.j.issn.0253-2727.2017.03.004.

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.

Meggendorfer M, Haferlach C, Kern W, Haferlach T

Haematologica 2017; (102(9)):1502-1510 doi:10.3324/haematol.2017.166173.

Management of older adults with myelodysplastic syndromes (MDS).

Luskin MR, Abel GA

Journal of geriatric oncology 2018; (9(4)):302-307 doi:10.1016/j.jgo.2017.12.002.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study.

Stauder R, Yu G, Koinig KA, et al.

Leukemia 2018; (32(6)):1380-1392 doi:10.1038/s41375-018-0089-x.

Myelodysplastic syndromes current treatment algorithm 2018.

Steensma DP

Blood cancer journal 2018; (8(5)):47 doi:10.1038/s41408-018-0085-4.

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Zeidan AM, Stahl M, DeVeaux M, et al.

Blood cancer journal 2018; (8(6)):55 doi:10.1038/s41408-018-0081-8.

Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid neoplasms: problem areas.

Goasguen JE, Bennett JM, Bain BJ, et al.

British journal of haematology 2018; (182(4)):526-533 doi:10.1111/bjh.15435.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, et al.

Blood 2018; (132(12)):1225-1240 doi:10.1182/blood-2018-04-843771.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Leitch HA, Buckstein R, Zhu N, et al.

Leukemia research 2018; (74()):21-41 doi:10.1016/j.leukres.2018.09.005.

Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it.

Zeidan AM, Shallis RM, Wang R, et al.

Blood reviews 2019; (34()):1-15 doi:10.1016/j.blre.2018.09.001.

Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy.

Aleshin A, Greenberg PL

Blood advances 2018; (2(20)):2787-2797 doi:10.1182/bloodadvances.2018015834.

Treatments targeting MDS genetics: a fool's errand?

DeZern AE

Hematology. American Society of Hematology. Education Program 2018; (2018(1)):277-285 doi:10.1182/asheducation-2018.1.277.

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P, Platzbecker U, Mufti GJ, et al.

The New England journal of medicine 2020; (382(2)):140-151 doi:10.1056/NEJMoa1908892.

SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.

Xiong B, Xue M, Yu Y, et al.

Clinical lymphoma, myeloma & leukemia 2020; (20(5)):329-339.e3 doi:10.1016/j.clml.2020.01.005.

Where Does Morphology Fit in Myelodysplastic Syndrome Diagnosis in the Era of Molecular Testing?

Giagounidis A, Haase S

Hematology/oncology clinics of North America 2020; (34(2)):321-331 doi:10.1016/j.hoc.2019.11.005.

Fueling clonal dominance through TRAFficking of NF-κB signaling.

Ueda K, Kumari R, Steidl U

Nature immunology 2020; (21(5)):489-490 doi:10.1038/s41590-020-0662-0.

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Malcovati L, Stevenson K, Papaemmanuil E, et al.

Blood 2020; (136(2)):157-170 doi:10.1182/blood.2020004850.

Iron overload regulate the cytokine of mesenchymal stromal cells through ROS/HIF-1α pathway in Myelodysplastic syndromes.

Hu J, Meng F, Hu X, et al.

Leukemia research 2020; (93()):106354 doi:10.1016/j.leukres.2020.106354.

Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant?

Sangiorgio VFI, Orazi A, Arber DA

Best practice & research. Clinical haematology 2020; (33(2)):101139 doi:10.1016/j.beha.2019.101139.

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome.

Novak P, Zabelina T, Wolschke C, et al.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2020; (26(11)):2047-2052 doi:10.1016/j.bbmt.2020.07.018.

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.

Garcia-Manero G, Chien KS, Montalban-Bravo G

American journal of hematology 2020; (95(11)):1399-1420 doi:10.1002/ajh.25950.

Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre.

Huang H, Xu C, Gao J, et al.

Blood cancer journal 2020; (10(8)):83 doi:10.1038/s41408-020-00349-4.

Mechanisms of lenalidomide sensitivity and resistance.

Martinez-Høyer S, Karsan A

Experimental hematology 2020; (91()):22-31 doi:10.1016/j.exphem.2020.09.196.

Outpatient transfusions for myelodysplastic syndromes.

Wood EM, McQuilten ZK

Hematology. American Society of Hematology. Education Program 2020; (2020(1)):167-174 doi:10.1182/hematology.2020000103.

Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.

Matos A, Magalhães SMM, Rauh MJ

Advances in experimental medicine and biology 2021; (1326()):1-10 doi:10.1007/5584_2020_608.

VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.

Huang H, Zhang W, Cai W, et al.

Experimental hematology & oncology 2021; (10(1)):23 doi:10.1186/s40164-021-00217-2.

Myelodysplasia Syndrome, Clonal Hematopoiesis and Cardiovascular Disease.

Veiga CB, Lawrence EM, Murphy AJ, et al.

Cancers 2021; (13(8)) doi:10.3390/cancers13081968.

Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.

Duetz C, Van Gassen S, Westers TM, et al.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 2021; (99(8)):814-824 doi:10.1002/cyto.a.24360.

How low risk are low risk myelodysplastic syndromes?

DeZern AE, Dalton WB

Expert review of hematology 2022; (15(1)):15-24 doi:10.1080/17474086.2022.2029698.

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.

Weinberg OK, Siddon A, Madanat YF, et al.

Blood advances 2022; (6(9)):2847-2853 doi:10.1182/bloodadvances.2021006239.

Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.

Buesche G, Teoman H, Schneider RK, et al.

British journal of haematology 2022; (198(1)):114-130 doi:10.1111/bjh.18163.

Iron Overload in Chronic Kidney Disease: Less Ferritin, More T2*MRI.

Nashwan AJ, Yassin MA, Mohamed Ibrahim MI, et al.

Frontiers in medicine 2022; (9()):865669 doi:10.3389/fmed.2022.865669.

Health-Related Quality of Life Assessment in Patients with Myelodysplastic Syndromes: Evidence from Randomized Clinical Trials.

Giesinger JM, La Nasa G, Sparano F, et al.

Clinical practice and epidemiology in mental health : CP & EMH 2021; (17(1)):307-314 doi:10.2174/1745017902117010307.

Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?

Hochman MJ, DeZern AE

The Lancet. Haematology 2022; (9(7)):e523-e534 doi:10.1016/S2352-3026(22)00138-7.

Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.

Sekeres MA, Taylor J

JAMA 2022; (328(9)):872-880 doi:10.1001/jama.2022.14578.

Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.

Kubasch AS, Giagounidis A, Metzgeroth G, et al.

Leukemia 2022; (36(10)):2519-2527 doi:10.1038/s41375-022-01669-z.

Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms.

Zhang Y, Wu J, Qin T, et al.

Leukemia 2022; (36(12)):2875-2882 doi:10.1038/s41375-022-01718-7.

The International Consensus Classification of myelodysplastic syndromes and related entities.

Hasserjian RP, Orazi A, Orfao A, et al.

Virchows Archiv : an international journal of pathology 2023; (482(1)):39-51 doi:10.1007/s00428-022-03417-1.

Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.

Makishima H, Saiki R, Nannya Y, et al.

Blood 2023; (141(5)):534-549 doi:10.1182/blood.2022018221.

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines.

DeFilipp Z, Ciurea SO, Cutler C, et al.

Transplantation and cellular therapy 2023; (29(2)):71-81 doi:10.1016/j.jtct.2022.11.014.

Transplant for TP53-mutated MDS and AML: because we can or because we should?

Versluis J, Lindsley RC

Hematology. American Society of Hematology. Education Program 2022; (2022(1)):522-527 doi:10.1182/hematology.2022000354.

Risk stratifying MDS in the time of precision medicine.

Cazzola M

Hematology. American Society of Hematology. Education Program 2022; (2022(1)):375-381 doi:10.1182/hematology.2022000349.

How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms.

Gurnari C, Xie Z, Zeidan AM

Clinical hematology international 2023; (5(1)):8-20 doi:10.1007/s44228-022-00024-4.

Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia.

Falini B, Martelli MP

American journal of hematology 2023; (98(3)):481-492 doi:10.1002/ajh.26812.

Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.

Kataoka A, Mizumoto C, Kanda J, et al.

International journal of hematology 2023; (117(6)):919-924 doi:10.1007/s12185-023-03532-y.

Risk prediction in MDS: independent validation of the IPSS-M-ready for routine?

Baer C, Huber S, Hutter S, et al.

Leukemia 2023; (37(4)):938-941 doi:10.1038/s41375-023-01831-1.

Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.

Maggioni G, Della Porta MG

Current opinion in hematology 2023; (30(2)):30-37 doi:10.1097/MOH.0000000000000752.

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Sauta E, Robin M, Bersanelli M, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023; (41(15)):2827-2842 doi:10.1200/JCO.22.01784.

AML classification in the year 2023: How to avoid a Babylonian confusion of languages.

Huber S, Baer C, Hutter S, et al.

Leukemia 2023; (37(7)):1413-1420 doi:10.1038/s41375-023-01909-w.

Supportive Care for Patients With Myelodysplastic Syndromes.

Stempel JM, Podoltsev NA, Dosani T

Cancer journal (Sudbury, Mass.) 2023; (29(3)):168-178 doi:10.1097/PPO.0000000000000661.

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.

Garcia-Manero G

American journal of hematology 2023; (98(8)):1307-1325 doi:10.1002/ajh.26984.

Incidence of and risk factors for myelodysplastic syndrome in patients with rheumatologic diseases.

Kim YE, Ahn SM, Oh JS, et al.

Rheumatology (Oxford, England) 2024; (63(5)):1305-1312 doi:10.1093/rheumatology/kead374.

Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

Lee WH, Tsai MT, Tsai XC, et al.

Blood cancer journal 2023; (13(1)):120.

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).

Stahl M, Bewersdorf JP, Xie Z, et al.

Blood reviews 2023; (62()):101128 doi:10.1016/j.blre.2023.101128.

Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.

Badar T, Madanat YF, Zeidan AM

Future oncology (London, England) 2023; (19(27)):1877-1889 doi:10.2217/fon-2023-0454.

Diagnosis and classification of myelodysplastic syndromes.

Hasserjian RP, Germing U, Malcovati L

Blood 2023; (142(26)):2247-2257 doi:10.1182/blood.2023020078.

Morphologic Characteristics of Myelodysplastic Syndromes.

Yuen LD, Hasserjian RP

Clinics in laboratory medicine 2023; (43(4)):577-596 doi:10.1016/j.cll.2023.06.003.

Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.

Kwon A, Weinberg OK

Clinics in laboratory medicine 2023; (43(4)):657-667 doi:10.1016/j.cll.2023.07.001.

Clonal evolution in inherited marrow failure syndromes predicts disease progression.

Schratz KE

Hematology. American Society of Hematology. Education Program 2023; (2023(1)):125-134 doi:10.1182/hematology.2023000469.

The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.

Khanna V, Lu R, Kumar J, et al.

Leukemia research 2024; (136()):107433 doi:10.1016/j.leukres.2023.107433.

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Bernard E, Tuechler H, Greenberg PL, et al.

NEJM evidence 2022; (1(7)):EVIDoa2200008 doi:10.1056/EVIDoa2200008.

Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?

Bejar R

NEJM evidence 2022; (1(10)):EVIDe2200165 doi:10.1056/EVIDe2200165.

From Histiocytoid Sweet Syndrome to Myelodysplasia Cutis: History and Perspectives.

Vignon-Pennamen MD, Battistella M

Dermatologic clinics 2024; (42(2)):209-217 doi:10.1016/j.det.2023.08.004.

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

Lee WH, Lin CC, Tsai XC, et al.

Blood cancer journal 2024; (14(1)):57.

Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.

Kewan T, Stahl M, Bewersdorf JP, Zeidan AM

Current hematologic malignancy reports 2024; (19(3)):138-150 doi:10.1007/s11899-024-00733-y.

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.

Sirenko M, Bernard E, Creignou M, et al.

Blood 2024; (144(11)):1221-1229 doi:10.1182/blood.2023023723.

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.

Gener-Ricos G, Rodriguez-Sevilla JJ, Urrutia S, et al.

Leukemia & lymphoma 2024; (65(9)):1233-1244 doi:10.1080/10428194.2024.2344061.

Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome.

Battaglia MR, Cannova J, Madero-Marroquin R, Patel AA

Current treatment options in oncology 2024; (25(6)):752-768 doi:10.1007/s11864-024-01217-0.

NGS panel enhance precise diagnosis of myeloid neoplasms under WHO-HAEM5 and International Consensus Classification: An observational study.

Ye X, Zheng Z, Wu Y, et al.

Medicine 2024; (103(24)):e38556 doi:10.1097/MD.0000000000038556.

Myelodysplasia cutis and VEXAS syndrome initially diagnosed as histiocytoid Sweet syndrome: A diagnostic pitfall.

Shimshak SJ, Jasmine S, Davis MDP, et al.

Journal of cutaneous pathology 2024; (51(11)):834-839 doi:10.1111/cup.14678.

Molecular monitoring of MDS: Watch this space!

Scheid C

British journal of haematology 2024; (205(3)):757-758 doi:10.1111/bjh.19644.

Assessing the Relevance of Non-molecular Prognostic Systems for Myelodysplastic Syndrome in the Era of Next-Generation Sequencing.

Lincango M, Andreoli V, Rivello HG, et al.

Annals of laboratory medicine 2025; (45(1)):44-52 doi:10.3343/alm.2024.0089.

Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents.

Raddi MG, Bencini S, Peruzzi B, et al.

Blood cancer journal 2024; (14(1)):127 doi:10.1038/s41408-024-01112-9.

Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions.

Salman H

Cancers 2024; (16(16)) doi:10.3390/cancers16162915.

The Significance of Detecting an Unusual Myeloblast Immunophenotype in a Presumptive Clinical Diagnosis of Myelodysplastic Syndromes.

Sameeta F, Wang W, Jelloul FZ, et al.

Archives of pathology & laboratory medicine 2025; (149(8)):717-726 doi:10.5858/arpa.2024-0228-OA.

Introduction to the Review Series on Myelodysplasia.

Mittelman M

Haematologica 2025; (110(2)):281-282 doi:10.3324/haematol.2023.284948.

The Diagnostic Spectrum of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Arber DA, Orazi A

Advances in anatomic pathology 2025; (32(4)):299-306 doi:10.1097/PAP.0000000000000485.

Validation of the diagnostic potential of 17 immunophenotypic core markers defined by the ELN-iMDS-Flow Working Group in an independent cohort of patients with MDS.

Veenstra CR, Alhan C, Westers TM, van de Loosdrecht AA

HemaSphere 2025; (9(3)):e70075 doi:10.1002/hem3.70075.

Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome.

Braish JS, Montalban-Bravo G, Ravandi F, et al.

Leukemia research 2025; (153()):107692 doi:10.1016/j.leukres.2025.107692.

Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.

Zugasti I, Lopez-Guerra M, Castaño-Díez S, et al.

Experimental hematology & oncology 2025; (14(1)):61 doi:10.1186/s40164-025-00652-5.

Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects.

Li X, Zou C, Xiang X, et al.

Biomolecules 2025; (15(6)) doi:10.3390/biom15060761.

Experiences with Higher-Risk Myelodysplastic Syndromes and Improving Patient-Centered Treatment Decision-Making: A Qualitative Study of Patients, Caregivers, and Providers.

Maravic MC, Land N, Prood N, et al.

Cancer management and research 2025; (17()):1215-1232 doi:10.2147/CMAR.S482570.

Clinical features and outcomes of myelodysplastic syndrome patients with iron overload: a single-center retrospective study.

Huang L, Wang Y, Zhang X, et al.

European journal of medical research 2025; (30(1)):600 doi:10.1186/s40001-025-02848-1.

Management of Anemia in Lower-Risk Myelodysplastic Syndromes/Neoplasms With Novel Agents.

Hoff FW, Chung SS, Zeidan AM, Madanat YF

JCO oncology practice 2026; (22(6)):961-967 doi:10.1200/OP-24-00910.

Kundalini Yoga for Improving Patient-Reported Outcomes in Patients Diagnosed with Myelodysplastic Syndromes: A Pilot Study.

Amitai I, Marcus R, Amitai Y, et al.

Acta haematologica 2025; 1-6 doi:10.1159/000547575.

Single-cell spatial mapping reveals dynamic bone marrow microarchitectural alterations and enhances clinical diagnostics in MDS.

Nachman R, Kopacz A, Unkenholz C, et al.

bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.10.02.680138.

Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.

Wang LY, Gao HT, Fu Q, et al.

British journal of haematology 2026; (208(2)):579-588 doi:10.1111/bjh.70271.

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

Santini V, Zeidan AM, Van Eygen K, et al.

Leukemia 2026; (40(2)):397-409 doi:10.1038/s41375-025-02831-z.

A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.

Bewersdorf JP, Mina A, Stahl M, Zeidan AM

Nature reviews. Clinical oncology 2026; (23(7)):481-500 doi:10.1038/s41571-026-01141-2.

Understanding the evolving role of early palliative care in myelodysplastic syndromes: a 2026 narrative review.

Niscola P, Gianfelici V, Giovannini M, et al.

Annals of hematology 2026; (105(5)).